Anti ly6g

Manufactured by BioXCell

Sourced in United States

Anti-Ly6G is a monoclonal antibody that binds specifically to the Ly6G antigen, which is expressed on the surface of neutrophils. It can be used for the identification and isolation of neutrophils in various research applications.

Automatically generated - may contain errors

Lab products found in correlation

21 protocols using anti ly6g

Orthotopic Mammary Tumor Model in BALB/c Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

10⁵ TuBo cells were injected orthotopically in the fourth mammary gland on the left side of BALB/c mice. Treatments started when tumor size reached an average of 80 mm³. Anti-Ly6G treatments consisted of two IP injections per week of 100 μg Anti-Ly6G (BioXCell; Cat#BE0075-1) or IgG2a isotype control (BioXCell; Cat#BE0089) in PBS. IWR-1 (Sigma; Cat#I0161) treatment consisted of six different intratumoral injections every two days using a dose of 5 mg/Kg in DMSO.

Salemme V., Vedelago M., Sarcinella A., Moietta F., Piccolantonio A., Moiso E., Centonze G., Manco M., Guala A., Lamolinara A., Angelini C., Morellato A., Natalini D., Calogero R., Incarnato D., Oliviero S., Conti L., Iezzi M., Tosoni D., Bertalot G., Freddi S., Tucci F.A., De Sanctis F., Frusteri C., Ugel S., Bronte V., Cavallo F., Provero P., Gai M., Taverna D., Turco E., Pece S, & Defilippi P. (2023). p140Cap inhibits β-Catenin in the breast cancer stem cell compartment instructing a protective anti-tumor immune response. Nature Communications, 14, 2350.

+ Open protocol

+ Expand

Cytokine Administration and Immune Cell Depletion in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice received the indicated doses of mrIL-13 (0.5 µg/dose; BioLegend), mrIFN-γ (1.5 µg/dose; BioLegend), or 10⁴ or 2.5 × 10⁵ IUs of mrIFN-β or mrIFN-αA (PBL Assay Science, Piscataway, NJ) by i.t instillation. Antibody depletions were performed as stated for each experiment. For anti-IFNAR1 blocking treatment (7 (link), 66 (link)), we used the following antibodies: 1.5 mg of anti-IFNAR1 (MAR1-5A3) monoclonal antibody (MAb) or IgG1 isotype control antibody (Leinco Technologies, St. Louis, MO) administered i.p. For IFN-α/IFN-β treatment (67 (link)), we used 0.25 mg of anti-IFN-α (RMMA-1) MAb/anti-IFN-β (RMMB-1) MAb or an IgG1 isotype control antibody (~95 and ~90% efficacy, respectively; PBL Assay Science, Piscataway, NJ) administered i.p. For anti-IFNAR1/Ly6G treatment, we used 1.75 mg of anti-IFNAR1 (MAR1-5A3) MAb or IgG1 isotype control antibody (Leinco Technologies; St. Louis, MO) administered i.p. and 0.25 mg of anti-Ly6G (1A8; average ~90% depletion) MAb or IgG2a isotype control antibody (Leinco Technologies, St. Louis, MO) administered i.t. For anti-Ly6C/Ly6G depletion treatment, we used 0.25 mg anti-Ly6G (1A8; average ~97% depletion) or 0.25 mg anti-Ly6C (both from Bio X Cell, West Lebanon, NH) MAb or IgG2a isotype control antibody (Leinco Technologies, St. Louis, MO) administered i.t. (see Fig. S7 in the supplemental material).

Shepardson K.M., Larson K., Morton R.V., Prigge J.R., Schmidt E.E., Huber V.C, & Rynda-Apple A. (2016). Differential Type I Interferon Signaling Is a Master Regulator of Susceptibility to Postinfluenza Bacterial Superinfection. mBio, 7(3), e00506-16.

+ Open protocol

+ Expand

In Vivo Neutrophil-Mediated Leishmania Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols

Neutrophils from bone marrow were purified from C57Bl/6 mice by negative selection using neutrophil isolation kit (Miltenyi Biotec). Purified neutrophils were cultured at 1.0–5.0 x 10⁷ total cells and were infected or not at different ratios with RFP LmRyn metacyclic promastigotes, serum opsonized by prior incubation for 30 min. in 5% normal mouse serum. After 3 hr incubation at 35°C, 5% CO₂, infection levels (RFP) and expression of apoptotic marker (Apoptosis Assay, Thermo Fisher) were quantified by FACS. For mice infection, neutrophils from bone marrow were infected with RFP LmRyn metacyclic promastigotes 1:8 ratio for 3 hours, and 2.0 x 10⁵ neutrophils were injected in the ears of C57Bl/6 and Axl^-/-Mertk^-/- mice. Neutrophils were depleted using a single i.p. injection of 1 mg of 1A8 (anti-Ly6G, BioXCell), or GL113 (control IgG, BioXCell). One day after treatment, ears were injected with 2 x 10⁵ RFP LmRyn metacyclic promastigotes in the dermis by i.d. injection in a volume of 10 μL. M279 (Amgen) is a rat IgG mAb, which blocks ligand binding to the CSF-1R. Mice were treated with 200 μg M279 or rat IgG (Sigma) intraperitoneally 3 times a week for 9 weeks. The efficiency and specificity of the depletions were evaluated in dermal cell preparations by FACS.

Chaves M.M., Lee S.H., Kamenyeva O., Ghosh K., Peters N.C, & Sacks D. (2020). The role of dermis resident macrophages and their interaction with neutrophils in the early establishment of Leishmania major infection transmitted by sand fly bite. PLoS Pathogens, 16(11), e1008674.

+ Open protocol

+ Expand

Combination Immunotherapy for Tumor Inhibition

Check if the same lab product or an alternative is used in the 5 most similar protocols

EL4 cells (4 × 10⁵ cells/mouse) or B16-F10 cells (1 × 10⁶ cells/mouse) were injected subcutaneously into the lower right flank of C57BL/6 J mice. Five days after inoculation with EL4 cells, mice received daily intraperitoneal (i.p.) injection of PBS or VPA (500 mg/kg, Sigma-Aldrich) until day 13. Anti-Ly-6G (clone: 1A8, 400 µg/mouse), anti-CD8α (clone: 2.43), and anti-NK1.1 (clone: PK136) antibodies (Abs) (200 µg/mouse, Bio X Cell) were injected i.p. on days 4, 7, and 10. The anti-PD-1 (clone: J43) Ab or IgG (both 200 µg/mouse, Bio X Cell) were injected i.p on days 5, 8, and 11. Eight days after inoculation with B16-F10 cells, mice received daily i.p. injection of PBS or VPA (500 mg/kg) until day 15. Anti-Ly-6G (400 µg/mouse), anti-CD8α and anti-NK1.1 Abs (200 µg/mouse) were injected i.p. on days 7, 10 and 13. The anti-PD-1 Ab or IgG (both 200 µg/mouse, Bio X Cell) were injected i.p. on days 8, 11, and 14. The tumor volume was calculated periodically using the following formula: Tumor volume (cm³) = 0.5 × length (cm) × width (cm)².

Xie Z., Ikegami T., Ago Y., Okada N, & Tachibana M. (2020). Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression. Oncoimmunology, 9(1), 1734268.

+ Open protocol

+ Expand

Tumor Immunotherapy with DMXAA

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice with tumors of 6 mm in diameter received one i.p. injection of DMXAA (23mg/kg in DMSO, Sigma) or 100 µl of 50% DMSO in PBS as control. For immune cell depletion, 200 µg of anti-CD8 antibody (BioXcell, clone 53–6.72 or 300 µg of anti-Ly6G (BioXcell, clone 1A8) were injected every 2 days starting one day before DMXAA treatment. Macrophages were depleted with PLX3397 (obtained via an MTA with Plexxikon Inc.), a CSF1-R signaling inhibitor. Mice were fed with chow containing PLX3397, or control chow, starting 48h before DMXAA treatment.

Weiss J.M., Guérin M.V., Regnier F., Renault G., Galy-Fauroux I., Vimeux L., Feuillet V., Peranzoni E., Thoreau M., Trautmann A, & Bercovici N. (2017). The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression. Oncoimmunology, 6(10), e1346765.

+ Open protocol

+ Expand

Neutrophil Depletion in Glycerol-Induced Muscle Injury

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

For neutrophil depletion, mice were injected via the tail vein with 200 µg per mouse of a neutrophil-depleting antibody (anti-Gr1; BioLegend, clone RB6-8C5) or the isotype control (IgG2b; BioXCell, clone LTF-2) 24 h before glycerol-mediated injury of the TA muscle. Subsequently, these mice were further injected by i.p with another neutrophil-depleting antibody (anti-Ly6G; BioXCell, clone 1A8, 200 µg per mouse) or the corresponding isotype control (IgG2a; clone 2A3, 200 µg per mouse) 48 h and 96 h after the first dose of neutrophil-depleting antibody. BALB/c male mice (The Jackson Laboratory, JAX#000651) at 3 months of age were utilized for these experiments because anti-Gr1 and anti-Ly6G antibodies work better in this strain to deplete neutrophils^{73 (link),135 (link)–137 (link)}.

Graca F.A., Stephan A., Minden-Birkenmaier B.A., Shirinifard A., Wang Y.D., Demontis F, & Labelle M. (2023). Platelet-derived chemokines promote skeletal muscle regeneration by guiding neutrophil recruitment to injured muscles. Nature Communications, 14, 2900.

+ Open protocol

+ Expand

Immune Cell Depletion Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Depletion of neutrophils and T-cell subsets was achieved by i.p. injection of 200 μg antibody (BioXCell, Lebanon, NH, USA) every 3 days, beginning 3 days prior to cell transplantation, using the following antibodies: anti-Ly6G (clone 1A8), anti-CD8α (clone 2.43), anti-CD4 (clone GK1.5), and anti-Vγ2 TCR (clone UC3-10A6). For macrophage and NK-cell depletion, 200 μg of Clodronate liposomes (Liposoma BV, Amsterdam, Netherlands) and anti-asialo GM1 (Cedarlane, Burlington, ON, Canada), respectively, was injected 24 hours before cell transplantation and 50 μg every 3 days after. Depletion of each cell type was confirmed by flow cytometry of peripheral blood mononuclear cell (PBMC) before injecting each new dose of antibodies (data not shown). Antibodies used for depletion were from different clones than those used in flow cytometry to confirm the depletion.

Farrokhi A., Rahavi M., Jo S., Jalili R., Lim C.J., Ghahsary A, & Reid G.S. (2022). Inflammatory Immune Responses Trigger Rejection of Allogeneic Fibroblasts Transplanted into Mouse Skin. Cell Transplantation, 31, 09636897221113803.

+ Open protocol

+ Expand

Neutrophil Depletion in Urinary Tract Infection

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Purified, in vivo grade (reconstituted in PBS 7.0 containing no preservatives or stabilizers) rat IgG2a isotype control antibody or monoclonal anti‐Ly6G (100 μg/100 μl, 1A8, BioXcell, Lebanon, NH) was injected I.P. on days −1, 0, and +1 with respect to transurethral inoculation with UPEC‐GFP (CFT073). Ly6G is expressed on myeloid cells including neutrophils (Privratsky et al., 2018 (link); Rose et al., 2012 ; Yu et al., 2016 (link)).

Purkerson JM P.h.D., Everett C.A, & Schwartz G.J. (2022). Ammonium chloride‐induced acidosis exacerbates cystitis and pyelonephritis caused by uropathogenic E. coli. Physiological Reports, 10(18), e15471.

+ Open protocol

+ Expand

Investigating Radiation-Induced Tongue Damage

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Doses of anti-IL-1R (anti-Ly6G (BioXcell), and anti-G-CSF (R&D Systems) neutralizing antibodies were based on previous studies (31 (link)–33 (link)). Isotype control antibodies dose and administration schedules are included (Supplementary Table 2). Mice were treated i.p. on days 0, 2, 4, 6, and 8 of the experiment with antibodies directed against IL-1R (300 µg/mouse or IgG isotype control (BioXcell) (300 µg/mouse), in age- and sex-matched controls. For the anti-Ly6G (150 µg/mouse) and anti-G-CSF (10 µg/mouse) mice were treated i.p. with both antibodies and controls (R&D Systems) on d7, followed by daily treatments of G-CSF on d8, 9, and 10 of the experiment. Mice were treated with α-IL-17A or isotype control (BioXcell) at a 150 µg/mouse on days 8 and 10 post irradiation. On day 11 following HNI, tongues were harvested and assessed for tongue damage by toluidine blue+ staining.

Saul-McBeth J., Dillon J., Lee A., Launder D., Kratch J.M., Abutaha E., Williamson A.A., Schroering A.G., Michalski G., Biswas P., Conti SR I.I.I., Shetty A.C., McCracken C., Bruno V.M., Parsai E.I, & Conti H.R. (2021). Tissue Damage in Radiation-Induced Oral Mucositis Is Mitigated by IL-17 Receptor Signaling. Frontiers in Immunology, 12, 687627.

+ Open protocol

+ Expand

Retro-orbital Administration of Clodronate Liposomes

Check if the same lab product or an alternative is used in the 5 most similar protocols

One hour before administration, clodronate (CLO) liposomes or control liposomes (Liposoma, Amsterdam, The Netherlands, #CP-005-005) were kept at room temperature. Per mouse, 200 µL liposomes (50 µg/g) was administered retro-orbitally after vortexing, using a 29 G insulin syringe (VWR, Leuven, Belgium,). Likewise, labeled BMDMs were vortexed prior to injection with a 29 G insulin syringe. Unless noted otherwise, 100 µL of cells suspended in DPBS were injected in the right orbital plexus of anesthetized mice at a concentration of 10 × 10⁶/mL [42 (link),43 (link)]. Anti-Gr-1 (Bioxcell, Lebanon, USA, #BE0075) or anti-Ly6G (Bioxcell, Lebanon, USA, #BE0075-1) depleting monoclonal antibodies were administered intraperitoneally at a dose of 250 µg per mouse in 100 µL DPBS [44 (link)].

Combes F., Sofias A.M., Mc Cafferty S., Huysmans H., De Temmerman J., Hak S., Meyer E, & Sanders N.N. (2019). Mononuclear but Not Polymorphonuclear Phagocyte Depletion Increases Circulation Times and Improves Mammary Tumor-Homing Efficiency of Donor Bone Marrow-Derived Monocytes. Cancers, 11(11), 1752.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!